Medulloblastoma is a malignant pediatric brain tumor with distinct molecular subgroups, including Group 3 tumors that are aggressive and resistant to conventional therapies. A study used the Connectivity Map (C-MAP) database to identify potential therapeutic agents for Group 3 medulloblastomas. Piperlongumine (PL) and Alsterpaullone (ALP) were identified as effective treatments for different subgroups of medulloblastomas. In vitro and in vivo studies confirmed the anti-proliferative effects of these compounds on medulloblastoma cells, with ALP showing specificity for Group 3 tumors. ALP was found to induce apoptosis, inhibit the AKT pathway, and downregulate cell cycle-related genes, including MYC. The study highlights the use of chemical genomics to identify compounds targeting specific molecular subgroups of medulloblastoma, such as ALP for Group 3 tumors. Targeting cyclin-dependent kinases (CDKs) with ALP offers a potential therapeutic strategy for MYC-dependent tumors like Group 3 medulloblastomas. Overall, the research demonstrates the potential of ALP as a targeted therapy for Group 3 medulloblastoma and emphasizes the importance of gene expression analysis and drug screening in identifying effective treatments for pediatric brain tumors.